A 52-year-old man with a 10-year history of type 2 diabetes mellitus on metformin and glipizide presents with persistent nausea, fatigue, and a fruity odor on his breath. Laboratory findings show: blood glucose 320 mg/dL, pH 7.28, HCO₃⁻ 14 mEq/L, serum osmolality 340 mOsm/kg, and serum ketones mildly elevated (β-hydroxybutyrate 3.5 mmol/L). Urinalysis shows 3+ glucose and 1+ ketones. The patient is alert and oriented. What is the most appropriate immediate next step?

Explanation

## Clinical Presentation: Euglycemic DKA vs. Classic DKA This patient presents with a variant of DKA called **euglycemic DKA (euDKA)** or **diabetic ketoacidosis with moderate hyperglycemia**, characterized by: - Mild-to-moderate hyperglycemia (320 mg/dL, not > 600 mg/dL as in classic DKA) - Metabolic acidosis (pH 7.28, HCO₃⁻ 14 mEq/L) - Elevated serum ketones (β-hydroxybutyrate 3.5 mmol/L) - Elevated serum osmolality (340 mOsm/kg) - Fruity breath odor (acetone) **Key Point:** euDKA is increasingly recognized in type 2 diabetics on SGLT2 inhibitors (though this patient is on metformin/glipizide). The pathophysiology is identical to classic DKA: **uncontrolled lipolysis → excessive FFA β-oxidation → ketone body overproduction**. ### Ketone Body Metabolism in DKA **High-Yield:** Ketone bodies are produced in the **liver mitochondria** via the following pathway: 1. **Lipolysis** (adipose tissue) → Free fatty acids (FFAs) 2. **β-oxidation** (liver mitochondria) → Acetyl-CoA 3. **Ketogenesis** (liver) → β-hydroxybutyrate (predominant, ~70%) and acetoacetate (~30%) 4. **Peripheral utilization** → Brain, heart, skeletal muscle metabolize ketones for energy In DKA, **ketone *production* exceeds peripheral *utilization***, leading to accumulation and severe metabolic acidosis. $$\text{Ketogenesis rate} \gg \text{Ketone utilization rate} \Rightarrow \text{Ketosis + Acidosis}$$ ### Why Insulin is the Definitive Therapy ```mermaid flowchart TD A[Insulin deficiency]:::outcome --> B[↓ Lipolysis inhibition]:::outcome B --> C[↑ FFA mobilization from adipose]:::outcome C --> D[↑ Hepatic FFA uptake]:::outcome D --> E[↑ β-oxidation in mitochondria]:::outcome E --> F[↑ Acetyl-CoA production]:::outcome F --> G[↑ Ketone body synthesis]:::outcome G --> H[Ketosis + Metabolic acidosis]:::urgent H --> I[IV Insulin infusion 0.1 U/kg/hr]:::action I --> J[Inhibits lipolysis]:::action J --> K[↓ FFA mobilization]:::action K --> L[↓ Ketone production]:::action L --> M[Ketosis resolves, pH normalizes]:::outcome ``` ## Management: Why Option 0 is Correct **Clinical Pearl:** Even though this patient is alert and osmolality is only mildly elevated (340 mOsm/kg), he has **metabolic acidosis with elevated ketones** — diagnostic of DKA. The management is identical to classic DKA: 1. **IV Insulin Infusion (0.1 U/kg/hr):** Suppresses lipolysis → ↓ FFA delivery to liver → ↓ ketone production. This is the **only intervention that halts ketone synthesis at the source**. 2. **IV 0.9% Saline:** Corrects hypovolemia, improves renal perfusion, and enhances urinary ketone excretion. 3. **Electrolyte Monitoring:** Insulin drives K⁺ intracellularly; glucose correction must be gradual (50–100 mg/dL/hr) to avoid cerebral edema. 4. **ICU Admission:** Indicated because of metabolic acidosis (pH 7.28) and need for continuous monitoring. **High-Yield:** The **hallmark of DKA is elevated serum ketones + metabolic acidosis**, regardless of glucose level. euDKA is easily missed because glucose is not markedly elevated, but the pathophysiology and treatment are identical. ## Monitoring Targets | Parameter | Initial | Target | |-----------|---------|--------| | pH | 7.28 | > 7.30 | | HCO₃⁻ | 14 mEq/L | > 18 mEq/L | | Serum K⁺ | ? | 4.0–5.0 mEq/L | | Blood glucose | 320 mg/dL | Decrease 50–100 mg/dL/hr | | β-hydroxybutyrate | 3.5 mmol/L | < 0.6 mmol/L | ## Why Other Options Are Wrong See **whyEachDistractorIsWrong** section below.